Labcorp Acquires MLM Medical Labs To Expand Global Clinical Trial Laboratory Network

Labcorp (LH) will offer the FDA-cleared Elecsys pTau-217 blood test, developed by Roche Diagnostics, to detect Alzheimer's-related amyloid pathology in individuals aged 55+ with cognitive decline. This is the first FDA-cleared single-biomarker test for both ruling in and out amyloid pathology, setting it apart from other options.

Labcorp (LH) stock fell 4.3% to $307.43 after its 2026 Investor Day, where it reaffirmed revenue guidance of $14.71B-$14.83B and EPS growth of 8.5%-11.5%. The market expected a guidance raise, and the lack of upside led to profit-taking. Broader market declines also pressured the stock.

Great Point Partners sold MLM Medical Labs to Labcorp. MLM, which quadrupled revenue and EBITDA under Great Point, offers clinical lab services globally. Labcorp gains expanded infrastructure. Financial terms were not disclosed.

Great Point Partners sold MLM Medical Labs to Labcorp. MLM, a provider of lab services for clinical trials, quadrupled revenue and expanded globally under GPP's ownership. Labcorp is the acquirer.

Labcorp (NYSE: LH) acquired MLM Medical Labs, expanding its global central laboratory network to four continents. The deal enhances Labcorp's biomarker and specialty testing capabilities, strengthening its position in clinical trial services. Financial terms were not disclosed.

Roche's Elecsys pTau217 assay and Labcorp's Alzheimer’s test received FDA clearance, enabling broader use in primary care. This shift requires health systems to adapt workflows, EHR systems, and clinician training. The operational challenge includes integrating results into clinical pathways to avoid alert fatigue and ensure actionable outcomes.